169 related articles for article (PubMed ID: 26003086)
1. In vitro characterization of luseogliflozin, a potent and competitive sodium glucose co-transporter 2 inhibitor: Inhibition kinetics and binding studies.
Uchida S; Mitani A; Gunji E; Takahashi T; Yamamoto K
J Pharmacol Sci; 2015 May; 128(1):54-7. PubMed ID: 26003086
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of Luseogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus.
Samukawa Y; Mutoh M; Chen S; Mizui N
Biol Pharm Bull; 2017; 40(8):1207-1218. PubMed ID: 28769002
[TBL] [Abstract][Full Text] [Related]
3. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice.
Zhang Y; Nakano D; Guan Y; Hitomi H; Uemura A; Masaki T; Kobara H; Sugaya T; Nishiyama A
Kidney Int; 2018 Sep; 94(3):524-535. PubMed ID: 30045814
[TBL] [Abstract][Full Text] [Related]
4. Binding interaction of SGLT with sugar and thiosugar by the molecular dynamics simulation.
Tamura Y; Miyagawa H; Yoshida T; Chuman H
Biochim Biophys Acta; 2015 Nov; 1848(11 Pt A):2799-804. PubMed ID: 26260238
[TBL] [Abstract][Full Text] [Related]
5. Luseogliflozin for the treatment of type 2 diabetes.
Seino Y
Expert Opin Pharmacother; 2014 Dec; 15(18):2741-9. PubMed ID: 25359155
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological and clinical profile of a new SGLT2 inhibitor, luseogliflozin (Lusefi®)].
Takahashi T; Yamamoto K
Nihon Yakurigaku Zasshi; 2015 Sep; 146(3):150-8. PubMed ID: 26354015
[No Abstract] [Full Text] [Related]
7. A simple and rapid LC-MS/MS method for quantitation of luseogliflozin in rat plasma and its application to a PK study.
Kobuchi S; Matsuno M; Kawamoto M; Kojima N; Ito Y; Yamashita M; Sakaeda T
Bioanalysis; 2017 Jan; 9(2):163-171. PubMed ID: 27960548
[TBL] [Abstract][Full Text] [Related]
8. Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.
Yabe D; Hamamoto Y; Seino Y; Kuwata H; Kurose T; Seino Y
Expert Opin Drug Saf; 2017 Oct; 16(10):1211-1218. PubMed ID: 28741382
[TBL] [Abstract][Full Text] [Related]
9. The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.
Nakatsu Y; Kokubo H; Bumdelger B; Yoshizumi M; Yamamotoya T; Matsunaga Y; Ueda K; Inoue Y; Inoue MK; Fujishiro M; Kushiyama A; Ono H; Sakoda H; Asano T
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28777298
[TBL] [Abstract][Full Text] [Related]
10. Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects.
Kumagai Y; Hasunuma T; Sakai S; Ochiai H; Samukawa Y
PLoS One; 2015; 10(10):e0139873. PubMed ID: 26444986
[TBL] [Abstract][Full Text] [Related]
11. Luseogliflozin, a SGLT2 Inhibitor, Does Not Affect Glucose Uptake Kinetics in Renal Proximal Tubules of Live Mice.
Zhang A; Nakano D; Kittikulsuth W; Yamashita Y; Nishiyama A
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360935
[TBL] [Abstract][Full Text] [Related]
12. N-Glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors.
Yamamoto Y; Kawanishi E; Koga Y; Sakamaki S; Sakamoto T; Ueta K; Matsushita Y; Kuriyama C; Tsuda-Tsukimoto M; Nomura S
Bioorg Med Chem Lett; 2013 Oct; 23(20):5641-5. PubMed ID: 23999047
[TBL] [Abstract][Full Text] [Related]
13. Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters.
Pajor AM; Randolph KM; Kerner SA; Smith CD
J Pharmacol Exp Ther; 2008 Mar; 324(3):985-91. PubMed ID: 18063724
[TBL] [Abstract][Full Text] [Related]
14. Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats.
Rahman A; Fujisawa Y; Nakano D; Hitomi H; Nishiyama A
Clin Exp Pharmacol Physiol; 2017 Apr; 44(4):522-525. PubMed ID: 28063156
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.
Chino Y; Samukawa Y; Sakai S; Nakai Y; Yamaguchi J; Nakanishi T; Tamai I
Biopharm Drug Dispos; 2014 Oct; 35(7):391-404. PubMed ID: 25044127
[TBL] [Abstract][Full Text] [Related]
16. Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent.
Hasegawa M; Chino Y; Horiuchi N; Hachiuma K; Ishida M; Fukasawa Y; Nakai Y; Yamaguchi J
Xenobiotica; 2015; 45(12):1105-15. PubMed ID: 26489961
[TBL] [Abstract][Full Text] [Related]
17. Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study.
Samukawa Y; Sata M; Furihata K; Ito T; Ueda N; Ochiai H; Sakai S; Kumagai Y
Clin Pharmacol Drug Dev; 2017 Sep; 6(5):439-447. PubMed ID: 28783873
[TBL] [Abstract][Full Text] [Related]
18. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Xu B; Lv B; Feng Y; Xu G; Du J; Welihinda A; Sheng Z; Seed B; Chen Y
Bioorg Med Chem Lett; 2009 Oct; 19(19):5632-5. PubMed ID: 19700318
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice.
Okauchi S; Shimoda M; Obata A; Kimura T; Hirukawa H; Kohara K; Mune T; Kaku K; Kaneto H
Biochem Biophys Res Commun; 2016 Feb; 470(3):772-782. PubMed ID: 26505796
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.
Takasu T; Yokono M; Tahara A; Takakura S
Biol Pharm Bull; 2019; 42(3):507-511. PubMed ID: 30828082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
